



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L34230GJ1999PLC086681

Date: 14th November, 2024

To,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Sub: Outcome of the Board Meeting held on Thursday, 14th November, 2024 pursuant to Regulation 30 and 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref.: Script Code: 524414

Dear Sir,

With reference to above captioned subject, pursuant to Regulation 30 & 33 of Chapter IV read with schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and in continuation to our submission on 11th November, 2024, regarding holding of the board meeting of Norris Medicines Limited (“**the Company**”), we would like to inform you that, the meeting of the Board of Directors of the Company held today, i.e., Thursday, 14th day of November, 2024, have inter alia, considered and approved Un-audited Financial Results along with Limited Review Report for the quarter ended 30th September, 2024.

A copy of the Un-audited Financial Results along with Statement of Asset and Liability, Cashflow Statement and Limited Review Report of the Auditors thereon issued in this regard is attached below.

We are arranging to publish the said Financial Results in newspapers in the format prescribed under Regulation 47 of Listing Regulations.

The details of commencement of the board meeting as follows:

- (a) Commencement time of the board meeting: 01:45 P.M.
- (b) Conclusion time of the board meeting: 02.15 P.M.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking you,
Yours truly,

For NORRIS MEDICINES LIMITED

VIMAL D
Digitally signed by
VIMAL D SHAH
Date: 2024.11.14
14:27:09 +05'30'

VIMAL DHIRENDRA SHAH
DIRECTOR
DIN: 01506655
Encl.: As above

BAHEDIA & ASSOCIATES



CHARTERED ACCOUNTANTS

SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Towards Valia Road,
GIDC Estate, ANKLESHWAR - 393 002. ☎ : (02646) 221708

CA. B. L. Bahedia

(B.Com., D.T.P., LL.B., FCA.)

Mobile No. : +91 98241 36264, 97252 20412

E-mail : bbahedia@yahoo.com/gmail.com

Web : www.bahediaassociates.icai.org.in

Ref. No. :

Date :

"Limited Review Report"

Review Report to The Board of Directors of M/S NORRIS MEDICINES LIMITED

We have reviewed the accompanying statement of Unaudited financial results of M/S NORRIS MEDICINES LIMITED, REGD. OFF 801/P, GIDC ESTATE, ANKLESHWAR-393002, for the quarter period ended 30th September, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 13/11/2024. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, BAHEDIA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FRN-114421W)

(CA. B.L. BAHEDIA)

PROPRIETOR

(M.NO.048066)

UDIN : - 24048066BKADNZ6211

PLACE: ANKLESHWAR
DATE: 13/11/2024



NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No.,L24230GJ1990PLC086581

Rs. In Lakhs



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2024

Sl. No.	Particulars	QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	(a) Revenue from Operations	126.84	72.49	255.53	199.33	350.17	563.56
	(b) Other Income	0.12	1.16	0.00	1.28	0.00	2.84
	Total Income From Operations (Net)	126.96	73.65	255.53	200.61	350.17	566.40
2	Expenses						
	a. Cost of Materials Consumed	17.51	55.09	128.27	72.60	241.35	315.93
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	75.35	-37.83	73.87	37.52	-2.97	-50.04
	c. Employee Benfit Expenses	28.95	34.31	47.65	63.26	107.38	182.05
	d. Finance Costs	8.48	8.45	8.62	16.93	17.23	36.98
	e. Depreciation and Amortisation Expense	13.29	13.18	14.48	26.47	28.80	57.15
	f. Other expenditure	19.49	37.07	30.26	56.56	67.48	134.12
	Total Expenses	163.07	110.27	303.14	273.34	459.27	676.19
3	Profit/ Loss before Tax (1-2)	-36.11	-36.62	-47.61	-72.73	-109.10	-109.79
4	Tax Expense						
	a: Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	b: Deferred Tax	0.00	0.00	0.00	0.00	0.00	8.89
5	Profit / Loss after Tax	-36.11	-36.62	-47.61	-72.73	-109.10	-118.68
6	Other Comprehensive Income						
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-36.11	-36.62	-47.61	-72.73	-109.10	-118.68
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.36	-0.37	-0.48	-0.73	-1.09	-1.20

FOR NORRIS MEDICINES LIMITED


VIMAL D SHAH
Managing Director




STATEMENT OF ASSETS AND LIABILITIES		
	As At 30.09.2024 Un audited	As At 31.03.2024 (Audited)
A. ASSETS		
1. Non Current Assets		
a) Property, Plant & Equipment	553.80	578.57
b) Capital Work in Progress		
c) Investment Property		
d) Financial Assets		
i) Investments	0.94	0.94
ii) Loans	1.30	1.35
iii) Others	40.17	41.78
e) Non Current Tax Assets (Net)	96.34	96.34
f) Other Non Current Assets	82.86	85.47
TOTAL NON CURRENT ASSETS	775.41	804.46
2. Current Assets		
a) Inventories	388.09	433.36
b) Financial Assets		
i) Trade Receivables	78.77	106.07
ii) Cash and Cash Equivalents	1.93	3.76
iii) Bank Balance other than "b" above.		
iv) Loans		
v) Others	54.11	71.09
TOTAL CURRENT ASSETS	522.90	614.27
TOTAL ASSETS	1298.31	1418.73
B. EQUITY & LIABILITIES		
1) Equity		
a) Equity Share Capital	992.58	992.58
b) Other Equity	-2428.31	-2,355.58
Total Equity	-1435.73	-1363.00
2) Non Current Liabilities		
a) Financial Liabilities - Borrowings	1858.29	1,859.17
b) Provisions		
c) Deferred Tax Liabilities (Net)		
d) Non Current Tax Liabilities (Net)		
Total Non - Current Liabilities	1858.29	1859.17
3) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	299.87	293.20
ii) Trade payables	181.16	177.61
iii) Other financial liabilities	113.62	170.85
b) Other Current Liabilities	0.00	-
c) Provisions	281.10	280.90
Total Current Liabilities	875.76	922.56
TOTAL EQUITY AND LIABILITIES	1298.31	1418.73
Notes:		
<p>1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13.11.2024. The above results have been subjected to Audit by the Statutory Auditors of the company.</p> <p>2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI circular dated 05.07.2016.</p> <p>3) The Company is having one segment only and therefore Segmental Reporting is not applicable.</p> <p>4) There are no exceptional/ extraordinary items during the quarter ended 30.09.2024</p> <p>5) Previous year/period figures have been regrouped /rearranged wherever necessary to make them comparable with current period figures</p>		
<p>For Norris Medicines Limited</p> <p> Vimal D Shah Managing Director</p>		
<p>Date: 13.11.2024 Place: Ankleshwar</p>		
		

NORRIS MEDICINES LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 30th September 2024

		30-09-2024	31-03-2024
		<u>Rs. Lakhs</u>	<u>Rs. Lakhs</u>
(A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit/Loss before tax and extraordinary items	72.73	118.68
	Adjustments for :		
	Depreciation & Amortisation	26.47	57.15
	Deferred Tax Liability	-	8.89
	Interest Income	-	1.19
	Interest Paid	16.93	36.98
	Profit/Loss on Investment in bonds	-	-
	Profit/Loss on sale of Fixed Assets	-	2.21
	Other Non Operating Income	-	-
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	29.33	14.64
	Adjustments for Changes in Working Capital		
	Increase/Decrease in Trade Debtors	27.29	3.97
	Increase/Decrease in Inventories	45.26	113.51
	Increase/Decrease in Loans & Advances	16.98	10.96
	Trade Payables and Other Liabilities	46.80	152.11
	Net cash from operations before taxation	42.73	31.61
	Tax Paid	-	-
	CASH FLOW BEFORE EXTRA ORDINARY ITEM	42.73	31.61
	Extra Ordinary Item	-	-
	NET CASH FROM OPERATING ACTIVITIES	13.40	16.97
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	1.69	0.10
	Sale of Fixed Assets	-	9.13
	Investments Made during the year	-	-
	Long Term Advances	4.28	5.13
	Receipt from Investment	-	-
	Interest Income	-	1.19
	Dividend Received	-	-
	Profit/Loss on sale of bonds	-	-
	Net Cash used in Investing Activities (B)	2.59	5.09
(C)	CASH FLOW FROM FINANCING ACTIVITIES:-		
	Share Capital	-	-
	Borrowings	0.89	16.65
	Interest paid	16.93	36.98
	Net Cash Used in Financing Activities (C)	17.82	20.33
	Net Increase/Decrease in Cash and Cash Equivalents (A+B+C)	1.83	1.73
	Cash and Cash equivalents - Opening balance	3.76	2.03
	Cash and cash equivalents - Closing balance	1.93	3.76
		1.83	1.73

For NORRIS MEDICINES LIMITED


Vimal Shah
Managing Director

